Weight-loss drugs such as Wegovy and Ozempic may become the new frontline warriors in treating and preventing drug and alcohol addiction, a large new study shows. The research, published Wednesday in ...

(The Conversation) – A patient of mine, a veteran who had tried to quit smoking for over a decade, told me that after he started a GLP-1 drug for his diabetes, he lost interest in cigarettes. He ...

Most of the genetic risk for developing a substance use disorder comes from genes that broadly affect how our brains process rewards, regulate impulses and weigh consequences—not from genes that ...

A major new study out of the Department of Veterans Affairs’ St. Louis Health Care System found that GLP-1 medications, the class of drugs that includes Ozempic, Wegovy, Mounjaro and Zepbound, are ...

Al-Aly is a physician and researcher at Washington University in St. Louis and chief of research at the VA Saint Louis Health Care System. At a dinner party recently, someone poured my friend a glass ...

There is new evidence that drugs like Ozempic can reduce a person's risk of addiction. A large study found that people who started taking GLP-1 drugs for weight loss or diabetes were less likely to ...

Evidence continues to mount suggesting that GLP-1 drugs may help people cut back on cigarettes, drinking and opioid use. Subscribe to read this story ad-free Get unlimited access to ad-free articles ...

GLP-1 receptor agonists may reduce the risk of developing and dying from substance use disorders, a study found. The study, led by researchers at St. Louis-based WashU Medicine and published March 4 ...

A popular class of drugs for treating diabetes and obesity may reduce addiction, including abuse of alcohol, tobacco, cannabis, opioids and cocaine, according to research published March 4 by ...

A large study of data from Veterans Affairs finds that people on GLP-1 drugs were less likely to develop substance abuse disorder or overdose.